Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Exosomes in Psoriasis: From Pathogenic Mechanisms to Therapeutic Innovations

Xu Q., Liu W., Zhang S., Zhou L.

Narrative Review on Immune Modulation, published in Clin Cosmet Investig Dermatol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Clin Cosmet Investig Dermatol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42328489
PMCID
PMC13281886
DOI
10.2147/ccid.s606845

Abstract (original English)

Psoriasis is a chronic recurrent inflammatory disease driven by keratinocytes and immune cells. Exosomes, as key mediators of intercellular communication, play multidimensional roles in this disease. In terms of pathogenic mechanisms, exosomes released from psoriatic lesions carry non‑coding RNAs and proteins that program T‑cell polarization, drive M1 macrophage activation, and amplify keratinocyte inflammation, thereby sustaining the IL‑23/Th17 immune axis. Translational breakthroughs have repurposed these same vesicles into diagnostic and therapeutic tools. Circulating exosomal fingerprints offer non‑invasive biomarkers for disease activity and psoriatic arthritis differentiation. Leveraging their biocompatibility and low immunogenicity, exosomes from mesenchymal stem cells, plants, and microbes serve as cell‑free platforms achieving immune regulation, antioxidant effects, and microecological repair. Engineering strategies-including cargo loading, membrane surface modification and intelligent microneedle delivery systems-further enhance targeting and efficacy. Despite these advances, clinical translation faces fundamental challenges: lack of production standardization, undefined core active components and insufficient high‑level clinical evidence. Future efforts should prioritize international standards, rational design, and rigorous trials to accelerate exosome‑based precisi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research